Journal Home > Volume 6 , Issue 1
Objectives:

Restore muscular trophism and voluntary contractile capacity through cell therapy in atrophied muscles in SCI patients.

Setting:

Out Patient Treatment, Universidad Maimonides, Buenos Aires, Argentina.

Methods:

After receiving spinal cord cell therapy and intensive rehabilitation, 7 chronic complete spinal cord injury (SCI) patients (4 people with paraplegia and 3 people with quadriplegia) regained muscular electrical activity in previously denervated territories. However, signs of severe muscular atrophy persisted. Looking to reverse chronic muscular atrophy, atrophied muscles with electrical activity were implanted with autologous type 1 macrophages (Mo1) and autologous tissue-specific T helper 1 Cells (Th1) associated with autologous muscular progenitor cells (MPC). The Mo1 and Th1 used cells were named Effector Cells (EC). Each muscle received between 6 to 8 implants, one every 6 weeks. Cellular therapy was combined with intensive rehabilitation program.

Results:

Sonogram and histological signs of recovery started eight weeks after the first implant. Sonograms showed progressively muscle volume increasing and gradually replacement of hyperechogenic muscle tissue by hypoechogenic muscle bands (resembling normal muscular structure). New bands were distributed parallel to the main muscle axis, along the entire muscular length. Histological samples of hypoechogenic bands showed new and normal muscular tissue. Changes were seen in 7/7 patients. Non-significant side events were detected in any patient over the 24 months of follow up.

Conclusions:

The results presented here suggest that the combination of immune and regenerative cell therapy may play an important therapeutic role in clinical and histological recovery of chronic muscular atrophy.


menu
Abstract
Full text
Outline
About this article

Local immunomodulation and muscle progenitor cells induce recovery in atrophied muscles in spinal cord injury patients

Show Author's information Gustavo A. MovigliaM. Teresita Moviglia BrandolinoDamián CoutoSamanta Piccone
Centre for Tissue Engineering and Cellular Therapy Research (CIITT), Universidad Maimonides, Buenos Aires C1405BCK, Argentina

Abstract

Objectives:

Restore muscular trophism and voluntary contractile capacity through cell therapy in atrophied muscles in SCI patients.

Setting:

Out Patient Treatment, Universidad Maimonides, Buenos Aires, Argentina.

Methods:

After receiving spinal cord cell therapy and intensive rehabilitation, 7 chronic complete spinal cord injury (SCI) patients (4 people with paraplegia and 3 people with quadriplegia) regained muscular electrical activity in previously denervated territories. However, signs of severe muscular atrophy persisted. Looking to reverse chronic muscular atrophy, atrophied muscles with electrical activity were implanted with autologous type 1 macrophages (Mo1) and autologous tissue-specific T helper 1 Cells (Th1) associated with autologous muscular progenitor cells (MPC). The Mo1 and Th1 used cells were named Effector Cells (EC). Each muscle received between 6 to 8 implants, one every 6 weeks. Cellular therapy was combined with intensive rehabilitation program.

Results:

Sonogram and histological signs of recovery started eight weeks after the first implant. Sonograms showed progressively muscle volume increasing and gradually replacement of hyperechogenic muscle tissue by hypoechogenic muscle bands (resembling normal muscular structure). New bands were distributed parallel to the main muscle axis, along the entire muscular length. Histological samples of hypoechogenic bands showed new and normal muscular tissue. Changes were seen in 7/7 patients. Non-significant side events were detected in any patient over the 24 months of follow up.

Conclusions:

The results presented here suggest that the combination of immune and regenerative cell therapy may play an important therapeutic role in clinical and histological recovery of chronic muscular atrophy.

Keywords: spinal cord injury, immunomodulation, chronic muscular atrophy, muscular progenitor cells

References(35)

[1]
Moviglia GA, Fernandez Viña R, Brizuela JA, et al. Combined protocol of cell therapy for chronic spinal cord injury. Report on the electrical and functional recovery of two patients. Cytotherapy 2006, 8: 202-209.
[2]
Moviglia GA, Varela G, Brizuela JA, et al. Case report on the clinical results of a combined cellular therapy for chronic spinal cord injured patients. J Spinal Cord 2009, 47: 499-503.
[3]
Tidball JG. Mechanisms of muscle injury, repair, and regeneration. Compr Physiol 2011, 1: 2029-2062.
[4]
Dias DA, Kim H, Holl D, et al. Reducing pericyte-derived scarring promotes recovery after spinal cord injury. Cell 2018, 173: 153-165.
[5]
Wick G, Backovic A, Rabensteiner E, et al. The immunology of fibrosis: innate and adaptive responses. Trends Immunol 2010, 31: 110-119.
[6]
Kharraz Y, Guerra J, Mann CJ, et al. Macrophage plasticity and the role of inflammation in skeletal muscle repair. Mediators Inflamm 2013: 491497.
[7]
Albanese GA, Moviglia–Brandolino MT, Piccone SL, et al. Electromyographic changes observed after combined treatment: Autologous stem cell implant and intensive rehabilitation in patients with complete, chronic spinal cord injury. J Neurol Sci 2015, 357: e425-426.
[8]
Shi X, Garry DJ. Muscle stem cells in development, regeneration, and disease. Genes Dev 2006, 20: 1692-1708.
[9]
Moviglia-Brandolino MT, Moviglia GA, Piccone SC, et al. Muscular trophism and voluntary contractile capacity improvement after intramuscular implant of autologous muscular progenitor cells in SCI patients. Cytotherapy 2017, doi: 10.1016/j.jcyt.2017.03.057.
[10]
Burnet FM. A modification of Jerne’s theory of antibody production using the concept of clonal selection. CA Cancer J. Clin 1976, 26: 119-121.
[11]
Sallusto F, Lenig D, Mackay CR, et al. Flexible programs of chemokine receptor expression on human polarized T Helper 1 and 2 lymphocytes. J Exp Med 1998, 187: 875-83.
[12]
Horwitz EM, Le Blanc K, Dominici M, et al. International Society for Cellular Therapy. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy. 2005, 7(5): 393-395.
[13]
Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006, 8(4): 315-317.
[14]
Galipeau J, Krampera M, Barrett J, et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016, 18(2): 151-159
[15]
Moviglia GA, Blasetti N, Pelayes D, et al. In vitro differentiation of adult adipose mesenchymal stem cells into progenitor retinal cells. Ophtalmic Reseach 2012, 48(Suppl 1): 1-5.
[16]
Buckingham M. Gene regulatory networks and cell lineages that underlie the formation of skeletal muscle. Proc Natl Acad Sci USA 2017, 114: 5830-5837.
[17]
Burattini S, Ferri P, Battistelli M, et al. C2C12 murine myoblasts as a model of skeletal muscle development: Morpho-functional characterization. Eur J Histochem 2004, 48: 223-233.
[18]
Kim YK, Choi ES, Kim KT, et al. Quantitative measurement of muscle atrophy and fat infiltration of the supraspinatus muscle using ultrasonography after arthroscopic rotator cuff repair. Ann Rehabil Med. 2018, 42(2): 260-269.
[19]
Kendall FP, McCreary EK, Provance PG. Muscles: Testing and Function. Baltimore: Williams & Wilkins; 1993.
DOI
[20]
National Cancer Institute. USA. Common terminology criteria for adverse events, v3.0 (CTCAE). http://ctep.cancer.gov/ forms/CTCAEv3.pdf. 2006, published in August 9, 2016.
[21]
Murphy S, Ohlendieck K. The extracellular matrix complexome from skeletal muscle. Chapter 4 from the book Composition and Function of the Extracellular Matrix in the Human Body. http://www.intechopen.com/books/composition- and-function-ofthe-extracellular-matrix-in-the-human-body, 2016
DOI
[22]
Zhang S, Sun A, Xu D, et al. Impact of timing on efficacy and safety of intracoronary autologous bone marrow stem cells transplantation in acute myocardial infarction: A pooled subgroup analysis of randomized controlled trials. Clin Cardiol 2009, 32: 458-466.
[23]
Gonçalves MA, de Vries AA, Holkers M, et al. Human mesenchymal stem cells ectopically expressing full-length dystrophin can complement Duchenne muscular dystrophy myotubes by cell fusion. Hum Mol Genet 2006, 15: 213-221.
[24]
Murphy MM, Lawson JA, Mathew SJ, et al. Satellite cells, connective tissue fibroblasts and their interactions are crucial for muscle regeneration. Development 2011, 138: 3625-3637.
[25]
Wick G, Grundtman C, Mayerl C, et al. The immunology of fibrosis. Annu Rev Immunol. 2013, 31: 107-135.
[26]
Wong VW, Paterno J, Sorkin M, et al. Mechanical force prolongs acute inflammation via T-cell-dependent pathways during scar formation. FASEB J 2011, 25: 4498-4510.
[27]
Kryczka J, Boncela J. Leukocytes: the double-edged sword in fibrosis. Mediators Inflamm 2015: 652035.
[28]
Randolph DA, Carruthers CJ, Szabo SJ, et al. Modulation of airway inflammation by passive transfer of allergen-specific Th1 and Th2 cells in a mouse model of asthma. J Immunol 1999, 162: 2375-2383
[29]
Moviglia GA, Varela G, Gaeta CA, et al. Cells induce in vitro bone marrow mesenchymal stem cells transdifferentiation to neural stem cells. Cytotherapy 2006, 8(3): 196-201.
[30]
Moviglia GA, Varela G, Saslavsky J, et al. Effector T cells (ETC) against normal tissue induce transdifferentiation of MSC to different cell lineage related with the specificity of the ETC. Cytotherapy 2006, 8(Sup 1) (222).
[31]
Moviglia GA, Grangeat AM, Croce EA, et al. Mesenquimal Stem Cells combined with Effector T Cells and low doses of Ozone therapy produce regeneration of damaged inter vertebral discs in rats. Cytotherapy. 2009, 11(Sup 1).
[32]
Moviglia GA, Trigo G, Blasetti N, et al. 24 hr bone tissue formation using mesenquimal stem cells combined with effector T cells and platelet enriched plasma on a matrix of hydroxyapatite. Feasibility and animal proof of principles. Cytotherapy. 2011, 13 (Sup 1).
[33]
Moviglia GA, Blasseti N. Fast method to produce autologous pancreatic islets from fat mesenchymal stem cells. Cytotherapy 2011, 13 (Sup 1).
[34]
Blasetti N, Ugartemendia LA, Moviglia GA. Adipose mesenchymal stromal cells (AMSC) differentiate into neural progenitor cells (NPC) after 24 hours of co culture with effector cells (EC) against central nervous system (CNS) proteins. Cytotherapy. 2014, 16(Suplement 4).
[35]
Richardson J, Uguartemendia L, Santa Coloma E, et al. Combined cell therapy associated with hyaluronic acid infusion for ad integrum repair of knee cartilage. Cytotherapy. 2016, 18(Suplement 4).
Publication history
Copyright
Rights and permissions

Publication history

Received: 18 September 2018
Accepted: 03 December 2018
Published: 30 December 2018
Issue date: December 2018

Copyright

© The author(s) 2018

Rights and permissions

© The authors 2018. This article is published with open access at http://jnr.tsinghuajournals.com

Return